Eli Lilly's $2.117 Billion Trading Day Lands 22nd in Market Activity

On March 26, 2025, Eli Lilly (LLY) recorded a trading volume of $2.117 billion, ranking 22nd in the day's stock market activity. The stock experienced a 3.00% decline, marking its second consecutive day of losses, with a total decrease of 4.41% over the past two days.

Eli Lilly and Company has announced its participation in the 2025 American Association for Cancer Research (AACR) Annual Meeting, where it will present new preclinical data for LY4050784, a selective inhibitor of SMARCA2, in collaboration with Foghorn Therapeutics.

Additionally, the company has revealed its expectations for 2024 full-year worldwide revenue, projecting approximately $45.0 billion, which represents significant growth from previous years.

Eli Lilly is also expanding its portfolio by acquiring all commercial and intellectual property rights to Organovo's FXR program for worldwide development, further strengthening its position in the pharmaceutical industry.